Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2009-05-15
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of a range of oglemilast doses. The study will
be 14 weeks in duration. All patients meeting the eligibility criteria will be randomized to
one of three doses of oglemilast or placebo.